These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 1958032)

  • 1. Monoclonal antibodies as carriers for delivering cytotoxic agents.
    Ménard S; Canevari S; Colnaghi MI
    Ann Ist Super Sanita; 1991; 27(1):87-9. PubMed ID: 1958032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cooperative mixtures of bispecific F(ab')2 antibodies for delivering saporin to lymphoma in vitro and in vivo.
    French RR; Courtenay AE; Ingamells S; Stevenson GT; Glennie MJ
    Cancer Res; 1991 May; 51(9):2353-61. PubMed ID: 2015599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies and immunoconjugates for cancer treatment.
    Baldwin RW; Byers VS; Pimm MV
    Cancer Chemother Biol Response Modif; 1988; 10():397-415. PubMed ID: 3079393
    [No Abstract]   [Full Text] [Related]  

  • 6. The design of cytotoxic-agent-antibody conjugates.
    Ghose T; Blair AH
    Crit Rev Ther Drug Carrier Syst; 1987; 3(4):263-359. PubMed ID: 2435417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
    Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
    J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
    Zhao XY; Schneider D; Biroc SL; Parry R; Alicke B; Toy P; Xuan JA; Sakamoto C; Wada K; Schulze M; Müller-Tiemann B; Parry G; Dinter H
    Cancer Res; 2005 Apr; 65(7):2846-53. PubMed ID: 15805286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody conjugates and therapeutic strategies.
    McCarron PA; Olwill SA; Marouf WM; Buick RJ; Walker B; Scott CJ
    Mol Interv; 2005 Dec; 5(6):368-80. PubMed ID: 16394252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
    Mazor Y; Noy R; Wels WS; Benhar I
    Cancer Lett; 2007 Nov; 257(1):124-35. PubMed ID: 17698286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotoxins (author's transl)].
    Richer G; Jansen FK; Gros P
    Nouv Presse Med; 1982 Apr; 11(17):1321-4. PubMed ID: 7079145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotoxins--theoretical and practical aspects.
    Hofstaetter T; Gronski P; Seiler FR
    Behring Inst Mitt; 1984 May; (74):113-21. PubMed ID: 6383320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells.
    Nam SM; Kim HS; Ahn WS; Park YS
    Oncol Res; 1999; 11(1):9-16. PubMed ID: 10451027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-cytotoxic agent conjugates for cancer therapy.
    Chen J; Jaracz S; Zhao X; Chen S; Ojima I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):873-90. PubMed ID: 16296784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2.
    Epstein AL; Khawli LA; Hornick JL; Taylor CR
    Cancer Res; 1995 Jun; 55(12):2673-80. PubMed ID: 7780984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-targeted drugs for the therapy of cancer.
    Pietersz GA; Krauer K
    J Drug Target; 1994; 2(3):183-215. PubMed ID: 7812691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations.
    Pimm MV
    Crit Rev Ther Drug Carrier Syst; 1988; 5(3):189-227. PubMed ID: 3060267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
    Weil-Hillman G; Runge W; Jansen FK; Vallera DA
    Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.